Abstract:MicroRNAs (miRNAs) constitute a family of small non-coding ribonucleic acids that are post-transcriptional regulators of messenger RNA (mRNA) complexity. While miRNAs are known to be dynamically regulated during CNS development, the roles of specific miRNAs in CNS aging and neurodegeneration are not well understood. This study examined miRNA abundance and signaling circuitry in Alzheimer's disease (AD) brain, in cytokine-, Aβ42- and ROS-stressed human neural primary cell lines and in Tg2576 transgenic mice fed a high-fat cholesterol (HFC) diet. AD and age-matched control post-mortem brain tissue; IL-1β, Aβ42 and ROS-stressed human neural (HN) cells in primary culture; high-fat cholesterol (HFC) diet stressed Tg2576 mice; total DNA, RNA and protein isolation and quality control; DNA arrays (Affymetrix, Santa Clara, CA); micro RNA (miRNA) arrays (LC Sciences, Houston, TX); miRNA panels; Northern analysis; RT-PCR; Western Immunoblotting; gel shift assay; miRNA construct transfection vectors; specific NF–κB and inflammatory transcription factor repression; bioinformatics (Sanger miRBASE, Cambridge UK). Of the total number of miRNAs expressed in the human brain, only a selective subset appear to be altered in the AD process. miRNAs encoding miR-9, miR-124a, miR-125b, miR-128, miR-132 and miR-219 were found to be abundantly represented in fetal hippocampus however they exhibited differential regulation in Alzheimer hippocampus. Specific increases in the abundance of miRNA-146a was found to coincide with down-regulation in the abundance of one prominent miRNA-146a target, complement factor H (CFH) mRNA, encoding an important regulatory glycoprotein in the brain's complement and inflammatory response. Promoter mapping, inhibitor studies and transfection-reporter studies showed that miRNA-146a is an NF–κB-sensitive gene. We also observed a specific up-regulation of miRNA-146a in cytokine IL-1β- and Aβ42-stressed human neural cells and in HFC-stressed Tg2576 mice, an effect that was reversed in part by the cholesterol biosynthesis inhibitor simvastatin. These data are consistent with the idea that altered miRNA-mediated processing of mRNA populations may contribute to atypical mRNA abundance, neural dysfunction and inflammatory signaling pathways in Alzheimer's disease. The use of anti-miRNA pharmacotherapeutic strategies are attractive because they have potential to silence entire families of pro-inflammatory pathogenic genes in Alzheimer's disease brain. Supported in part by NIA AG18031.

Novel upregulation of amyloid-β precursor protein (APP) by microRNA-346 via targeting of APP mRNA 5′-untranslated region: Implications in Alzheimer’s disease

Down‐regulated Expression of Microrna‐338‐5p Contributes to Neuropathology in Alzheimer's Disease

Exosomes Mediate APP Dysregulation <i>via</i> APP-miR-185-5p Axis

Targeting Iron Responsive Elements (IREs) of APP mRNA into Novel Therapeutics to Control the Translation of Amyloid-β Precursor Protein in Alzheimer's Disease

Iron and the Translation of the Amyloid Precursor Protein (APP) and Ferritin Mrnas: Riboregulation Against Neural Oxidative Damage in Alzheimer's Disease

Genome-wide Analysis of Mirna Signature in the APPswe/PS1ΔE9 Mouse Model of Alzheimer's Disease.

MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice.

An Iron-responsive Element Type II in the 5′-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript

Human microRNA (miR-20b-5p) modulates Alzheimer’s disease pathways and neuronal function, and a specific polymorphism close to the MIR20B gene influences Alzheimer’s biomarkers

Selective Translational Control of the Alzheimer Amyloid Precursor Protein Transcript by Iron Regulatory Protein-1

O2-03-06: Micro RNA-146A–mediated Signaling in Alzheimer's Disease

microRNA‐425 loss mediates amyloid plaque microenvironment heterogeneity and promotes neurodegenerative pathologies

Human microRNA-153-3p targets specific neuronal genes and is associated with the risk of Alzheimer's disease.

P3‐046: Understanding Brain Microrna Profiling in the Double Transgenic APP/PS1 Mouse Model of Alzheimer's Disease

Novel 5 ' Untranslated Region Directed Blockers of Iron-Regulatory Protein-1 Dependent Amyloid Precursor Protein Translation: Implications for Down Syndrome and Alzheimer'S Disease

Specific APP translation blockers as a therapeutic intervention for Alzheimer's disease

miR-30a-5p induces Aβ production via inhibiting the nonamyloidogenic pathway in Alzheimer’s disease

Potential Implications of miRNAs in the Pathogenesis, Diagnosis, and Therapeutics of Alzheimer’s Disease

Circulating Small Extracellular Vesicle-Derived miR-342-5p Ameliorates Beta-Amyloid Formation via Targeting Beta-site APP Cleaving Enzyme 1 in Alzheimer's Disease

MicroRNAs 99B-5P/100-5p Regulated by Endoplasmic Reticulum Stress Are Involved in Abeta-Induced Pathologies.

APP Intracellular Domain Acts As a Transcriptional Regulator of Mir-663 Suppressing Neuronal Differentiation.